What is the story about?
Ajanta Pharma Ltd on Friday (January 30) reported a 17.6% year-on-year increase in net profit for the third quarter, with profit rising to ₹274 crore compared with ₹233 crore in the corresponding period last year. Revenue for the quarter grew 20% year-on-year to ₹1,375 crore from ₹1,146 crore in the same quarter of the previous financial year.
Earnings before interest, tax, depreciation and amortisation (EBITDA) for the quarter stood at ₹382.5 crore, registering a 19.2% increase compared with ₹321 crore reported a year earlier. The company’s EBITDA margin for the quarter came in at 27.8%, marginally lower than 28% recorded in the year-ago period.
For the nine months ended December 31, 2025, revenue from operations increased 16% year-on-year to ₹4,031 crore from ₹3,478 crore in the corresponding period of the previous year. EBITDA for the nine-month period rose 10% to ₹1,061 crore compared with ₹962 crore, with an EBITDA margin of 26%.
Also Read: Ajanta Pharma shares gain 5% after in-licensing agreement with Biocon for Semgalutide
The company reported a mark-to-market forex loss of ₹61 crore during the nine-month period. Excluding this impact, EBITDA stood at ₹1,123 crore, reflecting a 15% year-on-year growth, with an EBITDA margin of 28%.
Profit after tax for the nine months ended December 2025 increased 14% to ₹789 crore from ₹695 crore in the year-ago period, with PAT margin at 20%. Return on capital employed stood at 34%, while return on net worth was at 26%.
As per IQVIA MAT December 2025 data, Ajanta Pharma’s India branded generics business delivered growth that exceeded the Indian Pharmaceutical Market (IPM) by 28%.
The outperformance was driven by higher volume growth, with volumes increasing 47% faster than the IPM, and strong traction from new product launches, which exceeded IPM growth by 59%.
Also Read: Ajanta Pharma Q2: Profit rises 20%, revenue grows; interim dividend declared
Shares of Ajanta Pharma Ltd ended at ₹2,770.50, up by ₹75.75, or 2.81%, on the BSE.
Earnings before interest, tax, depreciation and amortisation (EBITDA) for the quarter stood at ₹382.5 crore, registering a 19.2% increase compared with ₹321 crore reported a year earlier. The company’s EBITDA margin for the quarter came in at 27.8%, marginally lower than 28% recorded in the year-ago period.
For the nine months ended December 31, 2025, revenue from operations increased 16% year-on-year to ₹4,031 crore from ₹3,478 crore in the corresponding period of the previous year. EBITDA for the nine-month period rose 10% to ₹1,061 crore compared with ₹962 crore, with an EBITDA margin of 26%.
Also Read: Ajanta Pharma shares gain 5% after in-licensing agreement with Biocon for Semgalutide
The company reported a mark-to-market forex loss of ₹61 crore during the nine-month period. Excluding this impact, EBITDA stood at ₹1,123 crore, reflecting a 15% year-on-year growth, with an EBITDA margin of 28%.
Profit after tax for the nine months ended December 2025 increased 14% to ₹789 crore from ₹695 crore in the year-ago period, with PAT margin at 20%. Return on capital employed stood at 34%, while return on net worth was at 26%.
As per IQVIA MAT December 2025 data, Ajanta Pharma’s India branded generics business delivered growth that exceeded the Indian Pharmaceutical Market (IPM) by 28%.
The outperformance was driven by higher volume growth, with volumes increasing 47% faster than the IPM, and strong traction from new product launches, which exceeded IPM growth by 59%.
Also Read: Ajanta Pharma Q2: Profit rises 20%, revenue grows; interim dividend declared
Shares of Ajanta Pharma Ltd ended at ₹2,770.50, up by ₹75.75, or 2.81%, on the BSE.
